CMS Wound Care Policy Updates 2026: What Practitioners Must Know

CMS made more changes to wound care payment policy in 2026 than in any single year since the 2021 E/M overhaul. Skin substitute reimbursement was restructured entirely. New prior authorization requirements went live. Fee schedule adjustments shifted the economics of core wound care codes. And LCD coverage guidance was pulled for skin substitutes -- leaving practices to navigate medical necessity documentation without explicit roadmaps.

This is a consolidated reference of every major CMS wound care policy change effective in 2026, organized by what it means for your revenue and what operational changes your practice needs to make.

Medicare Physician Fee Schedule: Wound Care Code Adjustments

The 2026 Medicare Physician Fee Schedule applied the standard conversion factor update across all physician services, including wound care procedure codes. The conversion factor was set at $32.35, a slight decrease from the 2025 rate. For wound care practices, the practical impact falls on the codes you bill most frequently.

Debridement Codes (97597, 11042)

Selective debridement (97597) and excisional debridement (11042-11047) remain the most-billed wound care procedures. The 2026 fee schedule maintained the existing RVU structure for these codes, meaning reimbursement tracked the conversion factor adjustment. For 97597, the national Medicare payment holds near $85. Excisional debridement codes (11042 at approximately $140, 11043 near $245) follow the same pattern.

The RVU values for debridement codes were not individually revised in 2026. Revenue impact is tied to the conversion factor, not a code-specific revaluation. If you bill 500+ debridement procedures annually, the conversion factor adjustment translates to a modest per-claim reduction that compounds across volume.

For the full code reference, see our Wound Care CPT Codes 2026 guide.

Skin Substitute Application Codes (15271-15278)

Application codes 15271-15278 remain in the fee schedule, but the reimbursement structure for the products themselves changed dramatically. The application codes still pay for the physician work of applying the graft. What changed is the product reimbursement -- CTPs are now reimbursed at a flat rate of approximately $127.14 per square centimeter as incident-to supplies, replacing the previous product-specific ASP-based pricing. Practices that relied on high-ASP product margins are facing immediate compression.

E/M Codes (99213, 99214)

E/M codes 99213 and 99214 -- the two most common wound care visit codes -- saw minor adjustments consistent with the conversion factor change. 99213 holds near $93 and 99214 near $132 nationally. No RVU restructuring was applied to these codes in 2026. The E/M documentation framework (MDM-based or time-based) remains unchanged from the 2021 overhaul.

The operational takeaway: the fee schedule changes in 2026 are incremental on the procedure side. The real revenue disruption is in product reimbursement, not physician work values.

Skin Substitute Reclassification: The Largest Single Change

The most consequential policy change in 2026 is the reclassification of cellular and tissue-based products from individually priced items to incident-to supplies under the physician fee schedule. CMS collapsed hundreds of product-specific C-codes into a smaller set of Q-codes with standardized per-cm² reimbursement.

What happened: CTP products that previously had unique C-codes with ASP-based reimbursement (often $300-$500+ per cm²) now bill under Q-codes at the flat ~$127.14/cm² rate. Approximately 158 products were dropped from Medicare coverage entirely, leaving roughly 18 products on the approved list.

Revenue impact: For practices using premium grafts, per-application reimbursement dropped by 50-75%. Practices must renegotiate product acquisition costs or switch to lower-cost alternatives that maintain margin at the new reimbursement level. Product selection is now a financial decision as much as a clinical one.

What to do now: Audit your current product formulary against your MAC's approved list. Renegotiate supplier contracts based on the new reimbursement ceiling. Model your per-application margin at $127.14/cm² and eliminate products where acquisition cost exceeds reimbursement.

For the full breakdown, see our Medicare Skin Substitute Changes 2026 deep dive.

LCD Revisions: Coverage Guidance Withdrawn, Requirements Unchanged

Most MACs withdrew their Local Coverage Determinations for skin substitutes in early 2026. This was not deregulation. The underlying medical necessity requirements remain fully in effect -- practices are still required to document conservative wound care trials, serial wound measurements, vascular assessments, and clinical justification for advanced therapies.

What changed is that the explicit LCD checklist documenting exactly which elements a MAC reviewer expects is no longer published. Practices that built their documentation workflows around specific LCD requirements (L33831, L37166, L38720) now need to ensure their documentation meets the general Medicare medical necessity standard without LCD-specific guardrails.

Debridement and NPWT LCDs remain active in most jurisdictions. The LCD withdrawals are concentrated in skin substitute coverage. Check your MAC's current LCD status -- this varies by jurisdiction.

For LCD compliance strategies, see our Wound Care LCD guide.

WiSeR Model Expansion

CMS expanded the Wound Care Innovative, Safe, and Effective Treatments (WiSeR) model in 2026, adding mandatory prior authorization requirements for skin substitute applications in selected states. Under WiSeR, Medicare requires an approved PA number before any CTP application -- claims submitted without it receive a non-appealable denial.

The WiSeR PA requires documentation of wound type, 30+ days of failed conservative care with serial measurements, ABI for lower extremity wounds, and the specific product Q-code to be applied. Processing takes 3-10 business days standard, with expedited review available for clinical urgency.

Operational impact: Practices in WiSeR states need a PA workflow that runs 5-10 business days ahead of any planned application visit. PA is product-specific -- switching products mid-treatment requires a new authorization. Maintain approved PAs for at least two products per patient to avoid delays when a primary product is unavailable.

For the complete WiSeR requirements, see our WiSeR Model guide.

Prior Authorization Pilot Changes

Beyond WiSeR, CMS continues to adjust its broader Medicare FFS prior authorization programs. In 2026, CMS has signaled ongoing evaluation of which service categories may be added to mandatory PA requirements. Wound care procedures like NPWT and hyperbaric oxygen therapy are not currently in the mandatory Medicare FFS PA program, but CMS has the authority to add categories without rulemaking.

Medicare Advantage plans continue to apply prior authorization aggressively across wound care categories. Most MA plans require PA for skin substitutes, NPWT, and HBOT. Several MA plans expanded PA requirements in 2026 to include serial debridement beyond a threshold number of visits.

The trend is clear: PA burden is increasing, not decreasing. Practices without a dedicated PA workflow are absorbing preventable delays and denials.

For the full prior authorization breakdown, see our Prior Authorization Guide.

Medicare Advantage Wound Care Coverage Trends

Medicare Advantage enrollment continues to grow, and MA plans now cover the majority of Medicare beneficiaries in many markets. For wound care practices, MA plan behavior in 2026 is defined by three patterns.

Narrower product formularies. MA plans are restricting which skin substitute products they cover, often to a shorter list than Medicare FFS. If your practice serves MA patients, verify product coverage per plan before ordering inventory.

More aggressive utilization management. Visit frequency caps, treatment episode limits, and concurrent review requirements are becoming standard in MA wound care contracts. Practices billing high volumes of debridement or advanced wound therapy visits to MA plans should expect increased scrutiny and documentation requests.

Slower PA turnaround. Several MA plans extended their PA processing timelines in 2026, with standard reviews taking 10-15 business days compared to the Medicare FFS WiSeR timeline of 3-10 days. Build longer lead times into your scheduling workflow for MA patients.

Medicaid Wound Care Policy: State-Level Changes to Watch

Medicaid wound care coverage varies by state, and 2026 brought state-level changes that affect practices operating across multiple Medicaid programs.

Fee schedule updates: Several states updated their Medicaid wound care fee schedules in 2026, with most adjustments tracking Medicare rates. States that had not updated wound care reimbursement in multiple years may still pay significantly below Medicare. Verify your state's current Medicaid fee schedule against Medicare rates for every wound care code you bill.

Skin substitute coverage divergence: Some state Medicaid programs have not adopted the CMS reclassification framework and continue to cover skin substitutes under older product-specific codes. Others have followed Medicare's lead. The result is a patchwork where the same product may be covered, non-covered, or require different documentation depending on whether the patient is Medicare FFS, Medicare Advantage, or Medicaid.

Telehealth wound care policies: Multiple states expanded Medicaid telehealth coverage for wound care evaluations in 2026, allowing follow-up wound assessments and care plan modifications via telehealth. Requirements vary -- some states require an initial in-person evaluation, others allow telehealth-first visits for established patients with documented wound history.

What This Means for Your Practice

Every change above translates to one of two operational requirements: adjust your revenue model or adjust your workflow.

Revenue model: Skin substitute margin compression is the headline. If your practice depended on high-ASP product reimbursement, the business model needs restructuring -- renegotiate acquisition costs, consolidate to fewer covered products, and model profitability at the new reimbursement rates.

Workflow: PA requirements are expanding across payer types. Documentation standards are not relaxing even where LCDs have been withdrawn. Practices need systematic documentation workflows, PA tracking systems, and payer-specific compliance processes that run automatically -- not heroic individual effort on each claim.

The practices that absorb these changes fastest will be the ones that treated compliance infrastructure as a system, not a set of individual habits.